Alethia Young

Ms. Young is currently an advisor to Bicycle Therapeutics plc (Nasdaq: BCYC) after having served as its Chief Financial Officer from 2023-2026. Previously, Ms. Young was Chief Financial Officer at Graphite Bio, and prior to that, she served as Senior Biotech Analyst and Head of Research at Cantor Fitzgerald, managing the Equity Research Department covering small-cap, mid-cap and large-cap biotechnology companies. Before joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and President at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions. Ms. Young currently serves on the Board of Directors of PTC Therapeutics, Inc. (Nasdaq: PTCT).